INMED PHARMACEUTICALS INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
INMED PHARMACEUTICALS INC. (INM) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 13.85 million shares for the 3-month period ending 2021-12-31, per its 10-Q filed 2022-02-14.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-02-14
- INMED PHARMACEUTICALS INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 13.85M shares, a 127.33% increase year-over-year.
- INMED PHARMACEUTICALS INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 12.05M shares, a 130.76% increase year-over-year.
- INMED PHARMACEUTICALS INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 8.05M shares, a 54.11% increase year-over-year.
- INMED PHARMACEUTICALS INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-03-31 was 7.55M shares, a 44.60% increase year-over-year.
- INMED PHARMACEUTICALS INC. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 6.72M shares, a 28.71% increase from fiscal 2020.
- INMED PHARMACEUTICALS INC. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 5.22M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-12-31 | 13.85M shares 10-Q · filed 2022-02-14 | 12.92M shares 10-Q · filed 2022-02-14 | 11.31M shares derived: average of 3 quarters · filed 2022-02-14 | 10.37M shares derived: average of 4 quarters · filed 2022-02-14 |
| 2021-09-30 | 12.05M shares 10-Q · filed 2021-11-10 | 10.05M shares derived: average of 2 quarters · filed 2021-11-10 | 9.21M shares derived: average of 3 quarters · filed 2021-11-10 | 8.43M shares derived: average of 4 quarters · filed 2022-02-14 |
| 2021-06-30 | 8.05M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24 | 7.80M shares derived: average of 2 quarters · filed 2021-09-24 | 7.23M shares derived: average of 3 quarters · filed 2022-02-14 | 6.72M shares 10-K · filed 2021-09-24 |
| 2021-03-31 | 7.55M shares 10-Q · filed 2021-05-13 | 6.82M shares derived: average of 2 quarters · filed 2022-02-14 | 6.28M shares 10-Q · filed 2021-05-13 | 6.02M shares derived: average of 4 quarters · filed 2022-02-14 |
| 2020-12-31 | 6.09M shares 10-Q · filed 2022-02-14 | 5.66M shares 10-Q · filed 2022-02-14 | 5.51M shares derived: average of 3 quarters · filed 2022-02-14 | 5.44M shares derived: average of 4 quarters · filed 2022-02-14 |
| 2020-09-30 | 5.22M shares 10-Q · filed 2021-11-10 | 5.22M shares derived: average of 2 quarters · filed 2021-11-10 | 5.22M shares derived: average of 3 quarters · filed 2021-11-10 | 5.22M shares derived: average of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | 5.22M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24 | 5.22M shares derived: average of 2 quarters · filed 2021-09-24 | 5.22M shares derived: average of 3 quarters · filed 2021-09-24 | 5.22M shares 10-K · filed 2021-09-24 |
| 2020-03-31 | 5.22M shares 10-Q · filed 2021-05-13 | 5.22M shares derived: average of 2 quarters · filed 2021-05-13 | 5.22M shares 10-Q · filed 2021-05-13 | |
| 2019-12-31 | 5.22M shares 10-Q · filed 2021-02-11 | 5.22M shares 10-Q · filed 2021-02-11 | ||
| 2019-09-30 | 5.22M shares 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |